Hemab Therapeutics
NASDAQ: COAGIncorporated in Delaware · 5 known investors
Hemab is a biotechnology company developing targeted prophylactic therapies for people with serious bleeding and blood coagulation disorders that lack adequate treatment options. It focuses on shifting care toward prevention rather than management of bleeds.
BiotechHealthtech
Investors · 5
Competitors · 2
by search overlapBioworld14 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Adimab13 shared keywordsAdimab operates a yeast-based antibody discovery and engineering platform that produces fully human antibodies, heavy-chain antibodies, and multispecifics (including T-cell engagers) for biopharma partners. It offers services from antigen acquisition through preclinical lead generation, including AI-guided protein engineering, and works with partners through discovery, platform licensing, and technology-module collaboration models.
Companies competing with Hemab Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Hemab Therapeutics do?
- Hemab is a biotechnology company developing targeted prophylactic therapies for people with serious bleeding and blood coagulation disorders that lack adequate treatment options. It focuses on shifting care toward prevention rather than management of bleeds.
- Who are Hemab Therapeutics's investors?
- Hemab Therapeutics's investors include Access Biotechnology, Avoro Capital Advisors, HealthCap, Novo Holdings, Sofinnova Partners.